DBV TECHNOLOGIES SA-SPON ADR (DBVT) Fundamental Analysis & Valuation

NASDAQ:DBVT • US23306J2006

20.71 USD
-2.83 (-12.02%)
At close: Mar 11, 2026
21 USD
+0.29 (+1.4%)
After Hours: 3/11/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DBVT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall DBVT gets a fundamental rating of 3 out of 10. We evaluated DBVT against 519 industry peers in the Biotechnology industry. While DBVT seems to be doing ok healthwise, there are quite some concerns on its profitability. DBVT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. DBVT Profitability Analysis

1.1 Basic Checks

  • In the past year DBVT has reported negative net income.
  • DBVT had a negative operating cash flow in the past year.
  • DBVT had negative earnings in each of the past 5 years.
  • In the past 5 years DBVT always reported negative operating cash flow.
DBVT Yearly Net Income VS EBIT VS OCF VS FCFDBVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • DBVT has a worse Return On Assets (-85.56%) than 70.13% of its industry peers.
  • DBVT has a worse Return On Equity (-142.22%) than 62.04% of its industry peers.
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROIC N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
DBVT Yearly ROA, ROE, ROICDBVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • The Gross Margin of DBVT (91.34%) is better than 92.68% of its industry peers.
  • DBVT's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for DBVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
DBVT Yearly Profit, Operating, Gross MarginsDBVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. DBVT Health Analysis

2.1 Basic Checks

  • DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • DBVT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, DBVT has more shares outstanding
  • The debt/assets ratio for DBVT is higher compared to a year ago.
DBVT Yearly Shares OutstandingDBVT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DBVT Yearly Total Debt VS Total AssetsDBVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • DBVT has an Altman-Z score of 10.07. This indicates that DBVT is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 10.07, DBVT belongs to the top of the industry, outperforming 80.92% of the companies in the same industry.
  • A Debt/Equity ratio of 0.08 indicates that DBVT is not too dependend on debt financing.
  • DBVT has a worse Debt to Equity ratio (0.08) than 60.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 10.07
ROIC/WACCN/A
WACC8.15%
DBVT Yearly LT Debt VS Equity VS FCFDBVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • DBVT has a Current Ratio of 2.45. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.45, DBVT is doing worse than 70.91% of the companies in the same industry.
  • DBVT has a Quick Ratio of 2.45. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.45, DBVT is not doing good in the industry: 68.40% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.45
DBVT Yearly Current Assets VS Current LiabilitesDBVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. DBVT Growth Analysis

3.1 Past

  • DBVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.66%, which is quite impressive.
  • DBVT shows a strong growth in Revenue. In the last year, the Revenue has grown by 224.69%.
  • Measured over the past years, DBVT shows a small growth in Revenue. The Revenue has been growing by 0.50% on average per year.
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%N/A

3.2 Future

  • DBVT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.84% yearly.
  • Based on estimates for the next years, DBVT will show a very strong growth in Revenue. The Revenue will grow by 75.93% on average per year.
EPS Next Y-36.93%
EPS Next 2Y-12.4%
EPS Next 3Y10.53%
EPS Next 5Y15.84%
Revenue Next Year-55.09%
Revenue Next 2Y10.54%
Revenue Next 3Y21.57%
Revenue Next 5Y75.93%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBVT Yearly Revenue VS EstimatesDBVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
DBVT Yearly EPS VS EstimatesDBVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. DBVT Valuation Analysis

4.1 Price/Earnings Ratio

  • DBVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBVT Price Earnings VS Forward Price EarningsDBVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBVT Per share dataDBVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.4%
EPS Next 3Y10.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DBVT Dividend Analysis

5.1 Amount

  • DBVT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DBVT Fundamentals: All Metrics, Ratios and Statistics

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (3/11/2026, 8:00:02 PM)

After market: 21 +0.29 (+1.4%)

20.71

-2.83 (-12.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28
Earnings (Next)03-23
Inst Owners44.83%
Inst Owner Change144.45%
Ins Owners0.08%
Ins Owner Change29.3%
Market Cap1.14B
Revenue(TTM)15.73M
Net Income(TTM)-122.55M
Analysts80
Price Target24.23 (17%)
Short Float %2.36%
Short Ratio2.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.04%
PT rev (3m)58.92%
EPS NQ rev (1m)14.26%
EPS NQ rev (3m)34.59%
EPS NY rev (1m)10.26%
EPS NY rev (3m)38.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-91.14%
Revenue NY rev (3m)-91.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 299.52
P/FCF N/A
P/OCF N/A
P/B 13.21
P/tB 13.21
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-2.07
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.07
BVpS1.57
TBVpS1.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.34%
FCFM N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.61%
Cap/Sales 8.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.45
Altman-Z 10.07
F-Score2
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.42%
Cap/Sales(5y)23.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-36.93%
EPS Next 2Y-12.4%
EPS Next 3Y10.53%
EPS Next 5Y15.84%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%N/A
Revenue Next Year-55.09%
Revenue Next 2Y10.54%
Revenue Next 3Y21.57%
Revenue Next 5Y75.93%
EBIT growth 1Y-31.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.2%
EBIT Next 3Y27.74%
EBIT Next 5YN/A
FCF growth 1Y0.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.02%
OCF growth 3YN/A
OCF growth 5YN/A

DBV TECHNOLOGIES SA-SPON ADR / DBVT FAQ

Can you provide the ChartMill fundamental rating for DBV TECHNOLOGIES SA-SPON ADR?

ChartMill assigns a fundamental rating of 3 / 10 to DBVT.


What is the valuation status for DBVT stock?

ChartMill assigns a valuation rating of 0 / 10 to DBV TECHNOLOGIES SA-SPON ADR (DBVT). This can be considered as Overvalued.


Can you provide the profitability details for DBV TECHNOLOGIES SA-SPON ADR?

DBV TECHNOLOGIES SA-SPON ADR (DBVT) has a profitability rating of 1 / 10.